HXYT Collaborates with Leading Clinical Teams to Establish Beijing Key Laboratory of Solid Tumor Cell and Gene Therapy
BriSTAR Immunotech
Cellular Immunotherapy Product Developer
Recently, the Beijing Municipal Science and Technology Commission and the Zhongguan Village Science Park Management Committee announced the list of recognized key laboratories in Beijing for 2024. ByLeading expert in the field of digestive system tumors in China, Director Lin Shen from Peking University Cancer Hospital, in collaboration with enterprises within Zhongguancun Life Science ParkHuaxia Yingtai、Gaobo HospitalCo-built"Beijing Key Laboratory of Solid Tumor Cell and Gene Therapy"Successfully selected. This approval not only marks the recognition by the government and the industry of Huaxia Yingtai's strength in the field of cell and gene therapy, but also shows that the company has made initial achievements in promoting clinical research and product development for solid tumor cell therapy.
Beijing Key LaboratoryAs an important part of Beijing's scientific and technological innovation system, it is an important scientific and technological innovation base for gathering and cultivating outstanding innovative talents and carrying out high-level scientific research activities. It focuses on solving scientific and technological problems, promoting the transformation of scientific and technological achievements, and fostering new economic growth points.
Beijing Key Laboratory of Solid Tumor Cells and Gene TherapyThe establishment aims to focus on high-incidence and specific solid tumors in China, and is dedicated to breaking through the bottlenecks in solid tumor treatment from multiple dimensions, including the development of cell and gene therapy products, the construction of preclinical research platforms and evaluation systems, as well as the advancement of prospective clinical studies. The goal is to achieve significant breakthroughs in the field of cell and gene therapy for solid tumors. LaboratoryThrough the deep integration of clinical and basic research, we will further explore the mechanisms of resistance to gene therapy in solid tumors and strategies for reversal., optimize cell therapy products, cultivate a professional talent team, promote the vigorous development of the cell and gene therapy industry, and bring new hope to patients with advanced solid tumors.
The approval of the laboratory this time is a phased achievement of the in-depth cooperation between Huaxia Yingtai(Beijing)Biotechnology Co., Ltd. and Peking University Cancer Hospital, as well as Beijing GaoBo Hospital. It is also a strong proof of Huaxia Yingtai's innovation strength in the field of cell and gene therapy.. Huaxia Yingtai(Beijing)Biotechnology Co., Ltd., as a leading company in the industry,The original STAR-T technology platform combines the dual advantages of antigen-antibody target recognition and natural TCR signaling., showing technical characteristics such as high sensitivity, strong wettability, non-exhaustibility, and natural dual targets, has obtained good validation data in preclinical and preliminary clinical trials for multiple cancer types.
In the field of hematological tumor treatment, Huaxia Yingtai(Beijing)Biotechnology Co., Ltd. successively obtained targets in 2022 and 2024CD19/CD20 STAR-T and LILBR4 STAR-T ProductsChina's IND clinical trial implied permission; the clinical data of the product pipeline were successively reported at the 2020 ASH, 2021 EHA, 2023 AACR, and 2024 ASH international authoritative conferences.
In the field of solid tumor treatmentHuaxia Yingtai and other organizations such as Peking University Cancer Hospital have collaborated on several IIT studies targeting solid tumors like advanced liver cancer and gastric cancer, including those focused on advanced recurrent metastatic solid tumors.GPC3 STAR-T Study, which has initially demonstrated good clinical efficacy, gained high recognition from clinical researchers, and jointly undertaken key projects of the National Natural Science Foundation of China.
In addition to the clinical development of the above autologous cell products, Huaxia Yingtai(Beijing)Biotechnology Co., Ltd. also utilizes site-specific integration technology, combining the natural TCR signaling, high sensitivity, and strong tissue infiltration capabilities of STAR-T.Developed an allogeneic universal product. One of themCD19 STAR-T ProductIn exploratory clinical studies targeting severe systemic lupus erythematosus (SLE) and lupus nephritis patients, significant clinical efficacy was achieved, gaining high recognition from researchers.
The successful approval of the Beijing Key Laboratory of Solid Tumor Cell and Gene Therapy has injected new momentum into the development of Huaxia Yingtai(Beijing)Biotechnology Co., Ltd. in the field of solid tumor cell therapy.In the future, Huaxia Yingtai (Beijing) Biotechnology Co., Ltd. will continue to strengthen its cooperation with top domestic and international scientific research institutions and medical organizations, continuously advancing the research and development and clinical application of innovative cell and gene therapy technologies. By working together, they aim to open a new chapter in cell therapy for difficult-to-treat diseases such as solid tumors, helping Beijing become an international forefront in the biopharmaceutical field and contributing to humanity's efforts in overcoming major diseases.
